M22-574: Study of Treatment with Bispecific Antibody ABBV-383 in Relapsed/Refractory Multiple Myeloma After at Least 2 Prior Lines of Therapy
Condition: Multiple Myeloma
Sponsor: AbbVie
Full Title
Protocol M22-574: A Phase 3, Multicenter, Randomized, Open Label Study of ABBV-383 Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)
Study Treatment
BCMAxCD3 bispecific antibody ABBV-383 vs standard approved therapy
Eligibility/Info
Relapsed/refractory multiple myeloma treated with at least 2 prior lines of therapy. Prior therapy must have included an immunomodulating agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
Locations
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology
Need More Information?
Our team is here to help answer your questions and guide you through your options.